GSK Halts TIGIT Antibody Belrestotug Development Amid Clinical Setback; InnoCare Reports Q1 Revenue of RMB 380 Million
InnoCare
Innovative Drug Developer
GSK
Pharmaceutical R&D Manufacturer
BeOne
Developer of Molecular Targeted and Immune Anti-Tumor Drugs
Hamilton Biotech
Developer of New Drugs Based on Human Umbilical Cord Mesenchymal Stem Cells
Kanghong Pharmaceutical
Comprehensive pharmaceutical product manufacturer
'%20fill='%23FFFFFF'%3E%3Crect%20x='249'%20y='126'%20width='1'%20height='1'%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E)
© Amino Observation - Innovative Drug Team Original Production
Author | Huang Kai
TIGIT Development Hit Another Roadblock.
On May 13, GSK and iTeos Therapeutics announced the termination of the development of TIGIT antibody belrestotug due to failure to achieve expected efficacy in a Phase II lung cancer trial.
BeOne Medicines Issues 133 Million Shares to Wholly-Owned Subsidiary
Recently, BeOne Medicines announced that the company's board of directors had unanimously resolved in writing to approve the issuance of 133,000,000 company shares to BGNC2 within the authorized limit of the equity incentive plan previously approved by the company’s shareholders’ meeting. The new shares will be held by BGNC2 for the benefit of the incentive recipients.
In the past day, what hot topics in the pharmaceutical markets at home and abroad are worth paying attention to? Let Amino take you to find out.
/ 01 /
Capital Information
1) InnoCare's Q1 Revenue Reaches 380 Million Yuan
Recently, InnoCare released its first-quarter report for 2025. During the reporting period, total revenue increased by 129.9% year-over-year, reaching 380 million yuan. Of this, Orelabrutinib (orelabrutinib) grew by 89.2% year-over-year in the quarter, reaching 310 million yuan.
3) BeOne Medicines Issues 133 Million Shares to Wholly-Owned Subsidiary
Recently, BeOne Medicines announced that the company's board of directors unanimously agreed in writing to issue 133,000,000 company shares to BGNC2 within the authorized limit of the equity incentive plan previously approved by the shareholders' meeting. The new shares will be held by BGNC2 for the benefit of the incentive recipients.
/ 02 /
Pharmaceutical News
1) Hamilton Biotech's Human Umbilical Cord Mesenchymal Stem Cell Injection Receives Clinical Approval
On May 14, according to the CDE official website, Wuhan Hamilton Biotechnology Co., Ltd.'s human umbilical cord mesenchymal stem cell injection received clinical approval and is planned to be studied for the treatment of premature ovarian failure (without fertility needs).
2) BBM-P002 Injection from InnoCare Receives Clinical Approval
On May 14, according to the CDE official website, BBM-P002 Injection from Xinhua Traditional Chinese Medicine received clinical approval and is proposed to initiate research for the treatment of primary Parkinson's disease.
3) Xiangxue Life TAEST1901 Injection Receives Clinical Approval
On May 14, according to the CDE official website, Xiangxue Life's TAEST1901 injection received clinical approval for the treatment of advanced gastric cancer with the HLA-A*02:01 genotype and positive AFP tumor antigen expression.
4) AmoyDx Shingles mRNA Vaccine Receives Clinical Approval
On May 14, according to the CDE website, AIM Vaccine's shingles mRNA vaccine received clinical approval for the prevention of shingles caused by the reactivation of the varicella-zoster virus.
5) Kanghong Pharmaceutical's KH607 Tablet Receives Clinical Approval
On May 14, according to the CDE official website, Kanghong Pharmaceutical's KH607 tablet received clinical approval and is proposed for the treatment of postpartum depression.
6) BeOne Medicines' Injectable BGB-B455 Receives Clinical Approval
On May 14, according to the CDE website, BeOne Medicines' injectable BGB-B455 received clinical approval and is proposed to initiate research for the treatment of advanced solid tumors.
7) New Era Pharmaceutical's BCMA/CD3 Bispecific Antibody Receives Clinical Approval
On May 14, according to the CDE official website, New Times Pharmaceutical's BCMA/CD3 bispecific antibody received clinical approval and is proposed to conduct research on the treatment of systemic lupus erythematosus.
8) CStone Pharmaceuticals' CS2009 Injection Receives Clinical Approval
On May 14, according to the CDE official website, CStone Pharmaceuticals' CS2009 injection received clinical approval and is proposed to initiate research for the treatment of advanced solid tumors.
/ 03 /
Overseas Pharmaceutical News
1) GSK Acquires a New MASH Drug
On May 14, GSK announced that it would acquire the main asset of Boston Pharmaceuticals, the fibroblast growth factor 21 analog Efimosfermin alfa. GSK will pay up to $2 billion in cash consideration, including a $1.2 billion upfront payment and up to $800 million in success-based milestone payments.
2) GSK Terminates TIGIT Antibody Development
On May 13, GSK and iTeos Therapeutics announced the termination of the development of TIGIT antibody belrestotug due to failure to achieve expected efficacy in a Phase II lung cancer trial.
PS: Welcome to scan the QR code below and add the WeChat ID of Amino Jun for communication.